Augmedix Stock Beta
| AUGXDelisted Stock | USD 2.35 0.00 0.00% |
Augmedix fundamentals help investors to digest information that contributes to Augmedix's financial success or failures. It also enables traders to predict the movement of Augmedix Stock. The fundamental analysis module provides a way to measure Augmedix's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Augmedix stock.
Augmedix |
Augmedix Company Beta Analysis
Augmedix's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Augmedix Beta | -0.19 |
Most of Augmedix's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Augmedix is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Augmedix has a Beta of -0.19. This is 122.09% lower than that of the Health Care Equipment & Supplies sector and significantly lower than that of the Health Care industry. The beta for all United States stocks is 26.67% higher than that of the company.
Augmedix Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Augmedix's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Augmedix could also be used in its relative valuation, which is a method of valuing Augmedix by comparing valuation metrics of similar companies.Augmedix is currently under evaluation in beta category among its peers.
As returns on the market increase, returns on owning Augmedix are expected to decrease at a much lower rate. During the bear market, Augmedix is likely to outperform the market.
Augmedix Fundamentals
| Return On Equity | -3.3 | |||
| Return On Asset | -0.31 | |||
| Profit Margin | (0.46) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | 113.21 M | |||
| Shares Outstanding | 49.43 M | |||
| Shares Owned By Insiders | 1.50 % | |||
| Shares Owned By Institutions | 84.78 % | |||
| Number Of Shares Shorted | 1.07 M | |||
| Price To Book | 11.09 X | |||
| Price To Sales | 2.25 X | |||
| Revenue | 44.85 M | |||
| Gross Profit | 13.95 M | |||
| EBITDA | (17.68 M) | |||
| Net Income | (19.17 M) | |||
| Cash And Equivalents | 29.99 M | |||
| Cash Per Share | 0.80 X | |||
| Total Debt | 25.85 M | |||
| Debt To Equity | 1.54 % | |||
| Current Ratio | 2.89 X | |||
| Book Value Per Share | 0.21 X | |||
| Cash Flow From Operations | (15.44 M) | |||
| Short Ratio | 5.73 X | |||
| Earnings Per Share | (0.47) X | |||
| Target Price | 2.92 | |||
| Number Of Employees | 1.43 K | |||
| Beta | -0.19 | |||
| Market Capitalization | 116.16 M | |||
| Total Asset | 66.71 M | |||
| Retained Earnings | (144.96 M) | |||
| Working Capital | 33.2 M | |||
| Net Asset | 66.71 M |
About Augmedix Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Augmedix's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Augmedix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Augmedix based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Augmedix Stock
If you are still planning to invest in Augmedix check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Augmedix's history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |